Folic acid and vitamin B6 may prevent pancreatic cancer

Share This Post

A recent study published in the European Journal of Clinical Nutrition showed that diet may play a key role in preventing pancreatic cancer. The study investigated the link between pancreatic cancer risk and the intake of certain nutrients involved in methyl metabolism.

Zhang Jianjun, MD, associate professor of epidemiology at the Indiana University Fairbanks School of Public Health and senior author of the study, said: “Methylation is critical for DNA synthesis and methylation.” Methylation may be related to tumors. Formation is related to growth. Key nutrients for methyl metabolism include folic acid, vitamins B6 and B12, and methionine. The results showed that participants with the highest intake of folic acid had a 69% reduction in pancreatic cancer risk compared with those with the lowest intake. Vitamin B6 intake alone is not associated with pancreatic risk. However, when two nutrients are taken together, it is of practical significance. Large intake of folic acid and vitamin B6 can reduce the risk of pancreatic cancer by 76%.

The results of this study show that the intake of folic acid and vitamin B6 can help prevent pancreatic cancer. However, the American Cancer Institute (AICR) recommends that you get the nutrients you need from food and does not recommend the use of supplements to prevent cancer. AICR recommends eating a cancer-protective diet rich in folic acid, vitamin B6 and other nutrients to reduce the risk of cancer.

Folic acid is a water-soluble vitamin found in green leafy vegetables, beans, nuts and fruits. Vitamin B6 is present in many foods, including fortified grains, beans, poultry, fish and some vegetables and fruits, especially dark green leafy vegetables, papaya, oranges and cantaloupe.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy